Abstract
Objectives This descriptive study examined suspected xylazine co-involvement in law enforcement-recorded fentanyl overdoses in Pennsylvania (excluding Philadelphia), focusing on other drug involvement, naloxone administration, and survival.
Methods We examined data from 10,626 suspected fentanyl-involved overdoses (95 reportedly co-involving xylazine) recorded in the Pennsylvania Overdose Information Network (ODIN), January 2018-July 2024. All measures were based on law enforcement/first-responder assessment/report. We used relative frequencies, Fisher’s exact tests, and binomial logistic regression models, comparing overdoses reportedly involving xylazine and fentanyl versus those involving fentanyl but no xylazine.
Results Several drugs were reported in significantly larger proportions of overdoses in the fentanyl-xylazine group than the fentanyl-no-xylazine group: carfentanil (11.6% vs. 2.2%); other synthetic opioids (20.0% vs. 7.6%); methamphetamine (21.1% vs. 6.9%); and benzodiazepines (6.3% vs. 2.3%). Naloxone was administered in 41.1% of the cases reportedly involving xylazine, vs. 67.5% of the no-xylazine cases; 62.1% of the overdoses with xylazine recorded were fatal, compared to 27.7% of the fentanyl-no-xylazine overdoses. In multivariable regression models (among the suspected fentanyl overdoses recorded in ODIN, adjusting for age, gender, race/ethnicity, year, county, and other drugs reported): suspected xylazine involvement was associated with 65% lower odds of naloxone administration (Adjusted Odds Ratio [AOR] 0.35; 95% Confidence Interval [CI], 0.23-0.56) and 79% lower odds of survival (AOR 0.21; 95% CI, 0.13-0.35).
Conclusions In this study of law enforcement-recorded fentanyl overdose events in Pennsylvania, excluding Philadelphia: relative to fentanyl-no-xylazine overdoses, higher proportions of xylazine-fentanyl overdoses co-involved other synthetic opioids or methamphetamine, did not receive naloxone at the scene, and were fatal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Arizona State University waived ethical approval with a designation of "exempt" based on Federal Regulation 45CFR46 (4).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Conflicts of interests: None.
add the data source in the study title and shorten the title for simplicity; update the supplemental materials so that the sensitivity analyses tables can be included in the main results rather than in supplemental material only; and add additional description of the demographic characteristics to the results.
Data Availability
The data used in this study were obtained from a publicly-available dataset at: https://data.pa.gov/Opioid-Related/Overdose-Information-Network-Data-CY-January-2018-/hbkk-dwy3/about_data
